This black lily pad retreat is located in Logan, Ohio, and represents the art of mindful living. Secluded, and surrounded by ...

The OnePlus Pad 2 is an excellent update to the original thanks to its strong performance, bright display, booming speakers and incredible battery life. Though its unique centered back camera ...

If you are new to gardening, then choosing the best fertilizer for green beans can be a daunting task because there are a lot of options on the market. Meanwhile, there's no single bean fertilizer ...

Bloomberg / Contributor / Getty Images Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list ...

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the company widen its share of the booming weight-loss drug market.

The Food and Drug Administration said Wednesday that the shortage of Lilly’s Zepbound and Mounjaro is resolved. The agency added that there are “legal restrictions on making copies of FDA ...

Eli Lil­ly’s block­buster GLP-1 drug tirzepatide is fi­nal­ly back on track in the US af­ter two years of in­ter­mit­tent short­ages dri­ven by high de­mand, the … ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have ...

BioAge Labs is working on therapies for obesity as well as aging. It has plenty of cash, and it's collaborating with Eli Lilly and Novo Nordisk. Its pipeline programs aren't as early-stage as ...

(Reuters) -The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling ...

The article has been corrected. The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday. Eli Lilly’s ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...